Study of Lonidamine in Advanced Breast Cancer
Author Information
Author(s): J.L. Mansi, A. de Graeff, D.R. Newell, J. Glaholm, D. Button, M.O. Leach, G. Payne, I.E. Smith
Primary Institution: Breast Unit, The Royal Marsden Hospital
Hypothesis
Does Lonidamine have anti-tumor activity in patients with advanced breast cancer?
Conclusion
Lonidamine shows some activity against advanced breast cancer with low toxicity.
Supporting Evidence
- 11% of patients achieved a partial response.
- 53% of patients experienced mild myalgia.
- Pharmacokinetics showed absorption of Lonidamine in all patients.
Takeaway
This study tested a drug called Lonidamine on women with advanced breast cancer, and it helped some of them without making them very sick.
Methodology
32 patients with advanced breast cancer were given 600 mg of Lonidamine daily and monitored for response and side effects.
Limitations
The study had a small sample size and a short follow-up period.
Participant Demographics
Patients were mostly women with advanced breast cancer, aged less than 75 years.
Statistical Information
P-Value
p=0.02 for age correlation with pharmacokinetics
Want to read the original?
Access the complete publication on the publisher's website